NPHP1 Gene (Joubert Syndrome Type 4) Next-Generation Sequencing (NGS) Test in UAE

Executive Summary & Core Metrics

This NPHP1 gene sequencing test utilizes massively parallel Next-Generation Sequencing (NGS) to detect pathogenic variants associated with Joubert Syndrome Type 4 and related nephronophthisis, achieving a 99.9% diagnostic sensitivity. The test is fully accredited under the DHA regulatory framework for molecular diagnostics in Dubai Healthcare City.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Certified Processing
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM)
Clinical Guidance: Post-Test Clinical Consultation with a Consultant Medical Geneticist
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731

Test Overview & Methodology

The NPHP1 gene test employs Next-Generation Sequencing (NGS) to provide comprehensive coverage of the NPHP1 coding region and splice sites. Joubert Syndrome Type 4 is an autosomal recessive ciliopathy characterized by the molar tooth sign on brain MRI, hypotonia, and developmental delays. Early molecular diagnosis via NGS enables precise genetic counseling and management of renal complications. The table below contrasts our NGS-based approach with conventional Sanger sequencing.

Feature	Our Test (NGS)	Closest Alternative (Sanger Sequencing)
Precision	99.9% Analytical Sensitivity; full gene coverage (intronic & exonic)	~95% sensitivity; targeted known mutations only
Method	Massively Parallel NGS (Next Generation Sequencing)	Targeted Sanger Sequencing
Turnaround Time	3 to 4 Weeks	4 to 6 Weeks

Physician Insight & Safety Protocols

“A definitive molecular diagnosis of Joubert Syndrome Type 4 through NPHP1 sequencing is a critical step in guiding family planning and managing multisystem involvement. At DNA Labs UAE, we ensure that every result is correlated with clinical findings and accompanied by expert genetic counseling.”

– Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)

Advisory: Medication & Clinical Stability

Do not discontinue prescribed medications, including anticonvulsants or renal supportive therapies, prior to or during the genetic testing process without explicit consultation with your managing physician.

Exclusion Criteria & Safety Red Flags

Exclusion: Minors without documented parental or guardian informed consent (per Federal Decree-Law No. 4 of 2016 on Medical Liability).
Exclusion: Active use of blood-thinning agents without medical clearance for phlebotomy.
Emergency Red Flags: New-onset seizures, severe headache with vomiting, sudden vision loss, or breathing irregularities – seek immediate ER care. Genetic testing should be deferred until acute stabilization is achieved.

Patient FAQ & Clinical Guidance

1. What does the NPHP1 genetic test detect?

This test detects pathogenic mutations in the NPHP1 gene associated with Joubert Syndrome Type 4 and isolated nephronophthisis. These are ciliopathies that can lead to brain malformations, kidney cysts, and progressive renal failure. Clinical correlation with imaging and biochemical data, followed by genetic counseling, is essential for comprehensive management.

2. How is the sample collected for this test?

A standard peripheral whole blood sample (5-10 mL) is collected by our certified phlebotomists. DNA extraction is performed using ISO-certified protocols. Samples are transported via temperature-controlled cold-chain logistics directly to our CAP-accredited molecular diagnostics laboratory in Dubai Healthcare City.

3. How long do results take and what do they include?

Turnaround time is 3 to 4 weeks. The report includes a detailed sequence analysis, classification of variants per ACMG guidelines, clinical interpretation, and a telephonic consultation with a Consultant Medical Geneticist to discuss the findings and implications for family members.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE strictly complies with the national legislative framework governing genomic data and patient privacy:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): guaranteeing the security, confidentiality, and lawful processing of your genetic information.
Federal Law No. 2 of 2019: regulating the use of information and communication technology in health fields, ensuring telemedicine and digital health records meet stringent security standards.
Federal Decree-Law No. 4 of 2016 on Medical Liability: governing informed consent, clinical safety, and physician accountability in diagnostic procedures.

Clinical & Logistical Metadata

Test Name	NPHP1 Gene (Joubert Syndrome Type 4) Sequencing – NGS
Price (AED)	2,800 AED
Turnaround Time	3 to 4 Weeks
Sample Type / Matrix	Peripheral Whole Blood (5-10 mL) or Extracted Genomic DNA
Methodology Used	Massively Parallel Next-Generation Sequencing (NGS)
ICD-10-CM Code	Q04.3 (Joubert Syndrome), Q61.9 (Renal Tubular Cystic Disease)
LOINC Code	81265-9 (Hereditary nephropathy panel)
DHA Facility License & Laboratory Address	DHA License Number: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| Corporate Lab: DNA Labs UAE